Neurogene, Inc. (NGNE)
NASDAQ · Manufacturing · Pharmaceutical preparations
NGNE price, last 12 months
Key stats
- Previous close
- $31.25
- Open
- $31.31
- Day range
- $28.23 – $31.31
- 52-week range
- $15.93 – $43.66
- Volume
- 145.9K
- Avg volume (20 days)
- 318.1K
- Market cap
- $566.5M
Performance
Technicals and fundamentals
About Neurogene, Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $566.5M